Eli Lilly and CompanyLLY
Buy moreBuy more on a dip to our buy price, which is under Friday's $1,347.
- 11 good· Earnings beat
- 1 to watch· Pricier than rivals
$1,347.42−3.70 (−0.27%)
After hours $1,348.06 +0.1% · 7:59 PM ET on Friday
Price at 3:59 PM ET on Friday
Market closed · opens in 22h 24mNext open: Monday, Nov 23, 9:30 AM ETNYSE · Healthcare · Drug Manufacturers - General · Very large company
The price we'd buy LLY at comes with a free account
It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.
What would change it
Sources
- From the 10-Q for the quarter to Sep 30, reported Oct 29
- Yahoo Finance daily closes to Nov 20
Could move it to Keep
Next report
below23%
sales growth
Compared with the S&P 500
8 points
worse in one day
17 points
worse in five trading days
+29.9% in a yearsince Nov 20, 2025
The news behind our call
How LLY's risks changed
10-K filed Feb 12 against its 10-K from Feb 19, 2025
5reworded
Reworded
- Competition: We and our products face intense competition, and such competition could have a material adverse effect on our business.
- Pricing: Our business is subject to government price controls and other public and private restrictions on pricing, reimbursement, and access for our drugs, which could have a material adverse effect on our results of operations, reputation, or business.
- Supply chain: Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems or other negative outcomes.
- War & geopolitics: Our global operations subject us to risks, including as related to uneven economic growth or downturns, international trade, and other global disruptions, geopolitical tensions, or disputes.
- Litigation: We are party to litigation and investigations, which could adversely affect our business.
Oct 29 10-Q: no changes since.
Read 5 more
Reworded
- We and our products face intense competition, and such competition could have a material adverse effect on our business.Was: We and our products face intense competition, including from multinational pharmaceutical companies, biotechnology companies, and lower-cost generic and biosimilar manufacturers, and such competition could have a material adverse effect on our business.
- Our business is subject to government price controls and other public and private restrictions on pricing, reimbursement, and access for our drugs, which could have a material adverse effect on our results of operations, reputation, or business.Was: Our business is subject to increasing government price controls and other public and private restrictions on pricing, reimbursement, and access for our drugs, which could have a material adverse effect on our results of operations, reputation or business.
- Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems or other negative outcomes.Was: Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems.
- Our global operations subject us to risks, including as related to uneven economic growth or downturns, international trade, and other global disruptions, geopolitical tensions, or disputes.Was: Uneven economic growth or downturns or international trade and other global disruptions, geopolitical tensions, or disputes could adversely affect our business and operating results.
- We are party to litigation and investigations, which could adversely affect our business.Was: We are party to litigation and investigations related to our products, how we price or commercialize our products, and other aspects of our business, which could adversely affect our business, and we are self-insured for such matters.
What changed
Overview
Key figures
- Revenue (TTM)
- $86.5B
- Revenue growth, 1 year
- +45.5%
- Net income
- $27.6B
- EPS (diluted)
- $30.81
- Gross margin
- 83.6%
- Operating margin
- 51.3%
- Return on equity
- 86.0%
- Return on capital
- 42.7%
- Debt / equity
- 1.23
- Current ratio
- 1.39
- Dividend yield
- 0.51%
- Buyback yield
- 0.58%
Revenue by region
- United States$56.1B · 64%
- Europe$15.3B · 17%
- Rest of World$11.0B · 13%
- China$3.0B · 3.5%
- Japan$2.5B · 2.8%
Key facts
- Company value
- $1.27T
- Price / last year's earnings
- 43.7×
- Today's range
- 1341.771372.05
- Past year's range
- 847.501443.50
- Yesterday's close
- $1,351.12
- Swings vs the market
- 0.5×smaller
- Dividend yield
- 0.51%$6.92 a year